Jacobio Pharmaceuticals Group (SEHK:1167) Loss Narrows To C¥58.9m Challenging Bearish Narratives

Jacobio Pharmaceuticals Group (SEHK:1167) opened FY 2025 with first half revenue of C¥45.7 million and a basic EPS loss of C¥0.08, while trailing 12 month figures show revenue of C¥53.5 million and a basic EPS loss of about C¥0.19, underlining that the business is still in loss making territory on a full year view. The company has seen revenue move from C¥155.7 million with basic EPS of C¥0.02 in 2H 2024 to C¥45.7 million with basic EPS of C¥0.08 loss in 1H 2025, against a trailing 12 month net loss of about C¥146.0 million, so the latest print keeps the focus firmly on how quickly margins can tighten and losses can be contained.

See our full analysis for Jacobio Pharmaceuticals Group.

With the headline numbers on the table, the next step is to see how these results line up against the dominant narratives around Jacobio, and where the recent figures might start to challenge those views.

Curious how numbers become stories that shape markets? Explore Community Narratives

Losses Narrow From C¥169.1m To C¥59.0m Across Halves

• Net income moved from a loss of C¥169.1 million in 1H 2024 to a loss of C¥58.9 million in 1H 2025, with basic EPS shifting from a loss of C¥0.22 to a loss of C¥0.08 over the same halves.
• What stands out for the more bullish interpretation is that losses over the past five years are described as improving at about 42% per year. The move from a C¥169.1 million loss in 1H 2024 to C¥58.9 million in 1H 2025 fits that story of shrinking losses, even though the company is still loss making on a trailing 12 month basis with a C¥146.0 million net loss.

To see how other investors connect these shrinking losses with the long term story, Curious how numbers become stories that shape markets? Explore Community Narratives can help you put these numbers in broader context.

Revenue Swings From C¥0 To C¥201.4m Over Rolling Year

• Reported revenue was C¥0 in 1H 2024, C¥155.7 million in 2H 2024 and C¥45.7 million in 1H 2025, while the trailing 12 month snapshots reference revenue figures of C¥155.7 million, C¥201.4 million and C¥53.5 million at different points, highlighting how lumpy top line recognition has been across periods.
• Investors who focus on revenue growth forecasts of about 19.6% per year may view this pattern as consistent with an early stage biotech model where revenue can jump around. At the same time, the current trailing 12 month revenue figure of C¥53.5 million alongside a C¥146.0 million net loss also shows that even with expected growth, the path to covering those losses is still heavily dependent on how future periods line up.
• That tension between forecast growth and current loss making status is front and center when you compare the C¥201.4 million trailing revenue snapshot with the latest C¥53.5 million figure.
• It means any bullish view built around the 19.6% growth forecast needs to keep an eye on how often revenue looks closer to C¥45.7 million a half versus the higher points in the recent history.

P/B Of 6.3x Sits Above Sector Average

• The shares trade on a P/B of 6.3x versus about 4.7x for the wider Hong Kong biotech group and 6.2x for closer peers, so investors are paying a small premium to peer averages despite the trailing 12 month loss of C¥146.0 million.
• For more cautious investors, that premium price tag together with recent share price volatility over the last three months can reinforce a bearish tilt, because the valuation multiple is already higher than the broader industry while the business is still recording basic EPS of about a C¥0.19 loss on a trailing 12 month basis.
• Critics often point to this combination of a richer 6.3x P/B and ongoing losses when they question whether the current C¥7.09 share price fully reflects execution risk.
• The fact that there is no positive trailing EPS yet means bears can base their argument squarely on the gap between the premium multiple and the absence of current profitability.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Jacobio Pharmaceuticals Group's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Reading through these numbers, you can probably see both the worries and the potential, so move quickly, review the details yourself, and weigh up the 2 key rewards and 1 important warning sign before you decide what they really mean for you.

See What Else Is Out There

Jacobio is still posting sizeable losses, with C¥146.0 million trailing 12 month net loss and no positive EPS, while trading at a premium P/B multiple.

If you want ideas where pricing looks more modest relative to fundamentals, check out our 220 high quality undervalued stocks today and compare how those businesses stack up against this profile.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com